JP2022525795A - 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物 - Google Patents

高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物 Download PDF

Info

Publication number
JP2022525795A
JP2022525795A JP2021556591A JP2021556591A JP2022525795A JP 2022525795 A JP2022525795 A JP 2022525795A JP 2021556591 A JP2021556591 A JP 2021556591A JP 2021556591 A JP2021556591 A JP 2021556591A JP 2022525795 A JP2022525795 A JP 2022525795A
Authority
JP
Japan
Prior art keywords
methanol
dimethylpyrrolidine
compound
formula
dimethylpiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525795A5 (enExample
Inventor
ペルクマン，ベンジャミン
ベングソン，トレ
Original Assignee
アトロジー アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アトロジー アーベー filed Critical アトロジー アーベー
Publication of JP2022525795A publication Critical patent/JP2022525795A/ja
Publication of JP2022525795A5 publication Critical patent/JP2022525795A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021556591A 2019-03-20 2020-03-20 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物 Pending JP2022525795A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1903827.2 2019-03-20
GBGB1903827.2A GB201903827D0 (en) 2019-03-20 2019-03-20 New compounds and methods
PCT/GB2020/050762 WO2020188301A1 (en) 2019-03-20 2020-03-20 Heterocyclyl(phenyl)methanol compounds useful in the treatment of hyperglycaemia

Publications (2)

Publication Number Publication Date
JP2022525795A true JP2022525795A (ja) 2022-05-19
JP2022525795A5 JP2022525795A5 (enExample) 2024-08-27

Family

ID=66381053

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556591A Pending JP2022525795A (ja) 2019-03-20 2020-03-20 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物

Country Status (13)

Country Link
US (1) US20220152004A1 (enExample)
EP (1) EP3941468A1 (enExample)
JP (1) JP2022525795A (enExample)
KR (1) KR20210141622A (enExample)
CN (1) CN113784953A (enExample)
AU (1) AU2020243426A1 (enExample)
BR (1) BR112021018578A2 (enExample)
CA (1) CA3133768A1 (enExample)
GB (1) GB201903827D0 (enExample)
IL (1) IL286432A (enExample)
MX (1) MX2021011286A (enExample)
TW (1) TWI846843B (enExample)
WO (1) WO2020188301A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
GB202204085D0 (en) * 2022-03-23 2022-05-04 Atrogi Ab New compounds and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50100065A (enExample) * 1973-10-19 1975-08-08
JPS606658A (ja) * 1983-06-02 1985-01-14 チバ・ガイギ−・アクチエンゲゼルシヤフト 三置換オキサゾリジノン化合物
JP2002518301A (ja) * 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト 寄生虫を寄せ付けないための組成物
JP2002518298A (ja) * 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト 害虫を遠ざけるための組成物
JP2008512433A (ja) * 2004-09-07 2008-04-24 ソセイ・アール・アンド・ディー・リミテッド 炎症性障害及び疼痛の治療
JP2010530402A (ja) * 2007-06-21 2010-09-09 サノフイ−アベンテイス 置換インダゾール類、それらの調製および治療におけるその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985887A (en) * 1973-10-19 1976-10-12 Smithkline Corporation 3-Substituted-4-hydroxyphenyl-2-piperidylcarbinols as β-adrenergic stimulants
NO753594L (enExample) * 1974-10-30 1976-05-03 Scherico Ltd
FR2436779A1 (fr) * 1978-09-22 1980-04-18 Pharmindustrie Derives de pyrrolidine-2 methanol utilisables comme medicaments
FR2460929A1 (fr) * 1979-07-06 1981-01-30 Roussel Uclaf Nouveaux derives de l'a-phenyl 2-pyrrolidinemethanol et leur sels, procede de preparation, application a titre de medicaments et compositions les renfermant
GB0419828D0 (en) * 2004-09-07 2004-10-13 Arakis Ltd The treatment of inflammatroy disorders and pain
GB2435979A (en) * 2006-03-07 2007-09-12 Helen Theresa Haywood Door intercom telephone device
GB201714740D0 (en) * 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50100065A (enExample) * 1973-10-19 1975-08-08
JPS606658A (ja) * 1983-06-02 1985-01-14 チバ・ガイギ−・アクチエンゲゼルシヤフト 三置換オキサゾリジノン化合物
JP2002518301A (ja) * 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト 寄生虫を寄せ付けないための組成物
JP2002518298A (ja) * 1998-06-18 2002-06-25 ノバルテイス・アクチエンゲゼルシヤフト 害虫を遠ざけるための組成物
JP2008512433A (ja) * 2004-09-07 2008-04-24 ソセイ・アール・アンド・ディー・リミテッド 炎症性障害及び疼痛の治療
JP2010530402A (ja) * 2007-06-21 2010-09-09 サノフイ−アベンテイス 置換インダゾール類、それらの調製および治療におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YE, C. X. ET AL.: ""Dual catalysis for enantioselective convergent synthesis of enantiopure vicinal amino alcohols"", NATURE COMMUNICATIONS, vol. 9, no. 1, JPN6024006128, 2018, ISSN: 0005264923 *

Also Published As

Publication number Publication date
US20220152004A1 (en) 2022-05-19
KR20210141622A (ko) 2021-11-23
EP3941468A1 (en) 2022-01-26
CA3133768A1 (en) 2020-09-24
MX2021011286A (es) 2022-01-24
IL286432A (en) 2021-10-31
GB201903827D0 (en) 2019-05-01
TW202102473A (zh) 2021-01-16
TWI846843B (zh) 2024-07-01
CN113784953A (zh) 2021-12-10
AU2020243426A1 (en) 2021-11-04
WO2020188301A1 (en) 2020-09-24
BR112021018578A2 (pt) 2021-11-23

Similar Documents

Publication Publication Date Title
JP2022525795A (ja) 高血糖症の治療に有用なヘテロシクロリル（フェニル）メタノール化合物
ES2902073T3 (es) Beta-hidroxietilaminas sustituidas con heteroarilo para uso en el tratamiento de hiperglucemia
JP7346388B2 (ja) ベータ－ヒドロキシ複素環アミンおよび高血糖症の治療におけるそれらの使用
CN111148731B (zh) 氟苯基β-羟乙胺及其在治疗高糖血症中的用途
JP7046842B2 (ja) 高血糖症の治療のための化合物
JP2022525948A (ja) 高血糖症の治療に有用なヘテロアリール（ヘテロシクリル）メタノール化合物
JP2021526123A (ja) オートタキシン阻害剤とその使用
US11793774B2 (en) Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia
TW202220956A (zh) 新穎芳基氮雜雙環［２．１．１］己基甲醇及其醫藥用途
KR20240116482A (ko) 과혈당증 및 2형 당뇨병 치료를 위한 (r)-2-(tert-부틸아미노)-1-(5-플루오로피리딘-3-일)-에탄-1-올 헤미-타르트레이트 염의 결정질 형태
TW202438055A (zh) 用於處置高血糖及高血糖為特徵的疾患之取代羥甲基吡咯啶類
TW202444702A (zh) 用於處置高血糖及高血糖為特徵之疾患的雜環烷基β－羥基烷基胺類
HK40033371B (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia
HK40033371A (en) Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240510

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240819

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241029